Bharat Biotech, a Hyderabad based vaccine maker is developing a unique vaccine for Coronavirus. The global collaboration between FluGen, University of Wisconsin-Madison and Bharat Biotech is developing and testing an intranasal COVID-19 vaccine called CoroFlu. Bharat Biotech announced it today!
Build on M2SR, the backbone of FluGen’s flu vaccine candidate, CoroFlu is based on an invention by Gabriele Neumann, co-founder of FluGen and Yoshihiro Kawaoka, UW-Virologist. M2SR is a self-limiting influenza virus that induces the immune response.
Kawaoka’s lab will try inserting gene sequences in M2SR from SARS-CoV-2 which causes the deadly disease COVID-19 and test if a new vaccine created is inducing immunity against the novel coronavirus.
It will take around three to six months for CoroFlu vaccine concept testing in lab animal models at UW-Madison. Bharat Biotech’s role is to begin production scale-up for efficacy and safety on humans. CoroFlu could be tried on humans by the fall of 2020.
Dr. Raches Ella, Bharat Biotech’s Head of Business Development said, “Bharat Biotech will manufacture the vaccine, conduct clinical trials, and prepare to produce almost 300 million doses of vaccine for global distribution. Under the collaboration agreement, FluGen will transfer its existing manufacturing processes to Bharat Biotech to enable the company to scale up production and produce the vaccine for clinical trials.”
Until now, Bharat Biotech has commercialized 16 vaccines which also includes a vaccine for H1N1 flu which caused the pandemic in 2009.